1.. Introduction {#S0001}
================

*Ganoderma* sp. is a medicinal mushroom producing a group of frequently studied bioactive compounds. They belong to the kingdom of Fungi, division of Basidiomycota, class of Agaricomycetes, order Polyporales, family of Ganodermataceae and genus of Ganoderma. A search for "Ganoderma" in the database Index Fungorum displayed 409 species records, including synonyms (<http://www.speciesfungorum.org>). *Ganoderma* sp., especially *G. lucidum, G. tsugae* and *G. applanatum,* are well studied and have been in use in East Asian countries since the ancient times for the treatment of various diseases (Ofodile et al. [2005](#CIT0030); Paterson [2006](#CIT0032); Ferreira et al. [2015](#CIT0012)). Triterpenes and polysaccharides are considered key constituents isolated from fruiting bodies, gills, spores and mycelia for their bioactivities (Xia et al. [2014](#CIT0043)).

Literature reviews suggest, besides its antimicrobial activities, *Ganoderma* sp. components exhibit a variety of bioactivities, including anti-tumour, immune-modulatory, antioxidant, antihypertensive and anti-androgenic. Moreover, *Ganoderma* sp. is widely used for the remedy of various chronic diseases such as cancers, diabetes, hypertension and hepatitis (Ofodile et al. [2005](#CIT0030); Zhang et al. [2015](#CIT0046)). To date, most of the reviews on *Ganoderma* sp. have been focused on its anticancer and antioxidant activities and immune modulation (Sanodiya et al. [2009](#CIT0035)). Therefore, our basic aim is to provide a glimpse on the antimicrobial and anti-parasitic activities of *Ganoderma* sp. In addition, we also provide possible future prospect for research on *Ganoderma* sp. and its compounds.

In this review, we have performed literature searches in English (ISI Web of Science and Google Scholar) and Endnote X7 (online search, Pub Med) to find publications that described *Ganoderma* sp. for antimicrobial activities. We have used the keywords "Ganoderma" and "Antimicrobial". Finally, we filtered individual references to determine the relevancy to our study. The inclusion criterion was the study that provided data or results or discussion on the antimicrobial activities of *Ganoderma* sp.

2.. Antimicrobial and anti-parasitic bioactive compounds {#S0002}
========================================================

*Ganoderma* sp. has been reported as important sources of antimicrobial bioactive compounds. Terpenes, terpenoids and polyketides of farnesyl quonines types are the major secondary metabolites (SMs) produced by *Ganoderma* sp. In *Ganoderma* sp., more than 316 terpenes have been reported, with the majority of compounds from *G. lucidium* (Xia et al. [2014](#CIT0043)).

Chemical analysis of numerous *Ganoderma* sp. has showed Ganoderma Triterpenes (GTs) are mainly lanostanoid-type triterpene (Zhang et al. [2015](#CIT0046)). Among them, majority contain 30 or 27 carbon atoms, and some occasionally may contain 24 carbon atoms. These compounds possess the same parent skeleton, namely a *trans-*configuration of rings A/B, B/C, C/D and 10*β*, 13*β*, 14*α*, 17*β* substituent. In addition, the substituents are always found at the C-3, 7, 11, 12, 15, 22, 23, 24 and 25 positions of the parent nucleus (Xia et al. [2014](#CIT0043)). Thirty carbon terpenoids are usually formed by the fusion of two smaller terpenoids precursors, each containing 15 carbons sesquiterpene. Head-to-tail fashions linking of isoprene units to form linear chains and various cyclisations and rearrangements is the core mechanism to give cyclic terpenoids (Mothana et al. [2000](#CIT0026); Hill & Connolly [2013](#CIT0014)). The parent carbon skeleton of antimicrobial and anti-parasitic GTs is shown in [Figure 1](#F0001), from which it can be concluded that GTs are the most common antimicrobial and anti-parasitic compounds reported from *Ganoderma* sp.Figure 1.Parent carbon skeletons of triterpenoid and farnesyl quinone type of polyketide from *Ganoderma* sp. with antimicrobial and anti-parasitic activities.

Farnesyl quinone, a polyketide type, is the second most common antimicrobial and anti-parasitic compound from *Ganoderma* sp. Quinones are known to be oxidised derivatives of aromatic compounds and are often readily made from reactive aromatic compounds with electron-donating substituent such as catechols and phenols. Besides GTs, polypeptides, small peptides such as ganodermin, polysaccharide such as sacchachitin, and chitosan also possess antimicrobial and anti-parasitic properties (Mothana et al. [2000](#CIT0026); Wang & Ng [2006](#CIT0042); Sanodiya et al. [2009](#CIT0035); Chuang et al. [2013](#CIT0004)). Structures of antimicrobial and anti-parasitic compounds from *Ganoderma* sp. are shown in [Figure 2](#F0002a).Figure 2.Structure of compounds with antimicrobial and anti-parasitic activities from *Ganoderma* sp. Figure 2.(Continued). Figure 2.(Continued). Figure 2.(Continued).

3.. Isolation of antimicrobial and anti-parasitic bioactive compounds {#S0003}
=====================================================================

Extracts from fruiting bodies, both wild and cultivated, and mycelia from fermentation broth ([Tables 1](#T0001)--[4](#T0004)) are used for the isolation of antimicrobial and anti-parasitic bioactive compounds. Literatures divulge that most commonly ethanol (EtoAc) ([Tables 1](#T0001)--[4](#T0004)) is used to prepare crude extract; sometimes some researchers preferred other solvents such as chloroform (CHCl~3~), EtOH, and acetone (Isaka et al. [2016](#CIT0016)). In addition, our review reveals that hexane and ether are poorly used for the preparation of extract from *Ganoderma* sp. Moreover, some techniques such as microwave, ultrasound and enzyme treatments can facilitate the breakdown of the cell wall (Ferreira et al. [2015](#CIT0012)). Solvents like MeOH, EtOH, CH~2~Cl~2~, CHCl~3~ and aqueous -- both cold and hot -- are used for further purifications and isolation. Techniques such as thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), and column chromatography (CC) are used to facilitate the purification and isolation process (Huie & Di [2004](#CIT0015)). The general procedures of the isolation of antimicrobial and anti-parasitic compounds are shown in [Figure 3](#F0003). In addition, this outline can be used for other chemical investigations from *Ganoderma* sp.Table 1.Details of antibacterial activities of *Ganoderma* sp. parts, products and compounds.*Ganoderma*sp.Extraction SolventParts/products/compoundsTested bacteria strainsMethodMIC/MBCReferences*G. atrum*EtOH soluble acidic componentsFruiting bodies*S. aureus sub species Aureus, E. coli, B.subtilis, P. vulgaris*Micro dilution1.56-25mg/ml/3.125-25mg/ml(Li et al. [2012](#CIT0020))*G. lucidium*96%EtOHFruiting bodies*H. pylori* ATCC 43504, *S. aureus* ATCC 26003Micro plate Agar,\
Disc fusion Assay\<1.0mg/ml &\<10mg/ml resp./ND(Shang et al. [2013](#CIT0038))*G. colossum*Hexane: CH~2~Cl~2~(2:7)Colossolactone E(**6**), 23 hydroxycolossolactone E(**53**)*B. subtilis*IMI 347329, *P.syringae var* IMI 34748(ACTCC 19310)TLC Agar OverlayND(Lauretta Nwanneka Ofodile et al. [2011](#CIT0029))*G. pfeifferiBres.*CH~2~ Cl~2~Ganomycins A- B(**27--28**)*S. aureus*(ATCC 6538), *B. subtilis*(SBUG 14), *E. coli*(SBUG 13), *P. mirabilis* (SBUG 47), *S. marcescens*(SBUG 9), *M. flavus*(SBUG 16)Micro dilution2.5-25*µ*g/mL/ND(Mothana et al. [2000](#CIT0026))*G. applanatum*96%EtOHMycelia extract*B. cereus* (clinical isolate), *M. flavus*ATCC10240, *S. aureus*ATCC6538, *L. monocytogenes*NCTC7973, *E. coli*ATCC35218, *E. cloacae* (human isolate), *P. aeruginosa*ATCC27853 *and S. typhimurium*ATCC13311Colorimetric Microbial Viability Assay1.16--1.90mg/ml/2.54--4.00mg/ml(Cilerdzic et al. [2016](#CIT0006))*G. carnosum*96%EtOHMycelia extract*B. cereus* (clinical isolate), *M. flavus*ATCC10240, *S. aureus*ATCC6538, *L. monocytogenes*NCTC7973, *E. coli* ATCC35218, *E. cloacae* (human isolate), *P. aeruginosa*ATCC27853 *and S. typhimurium*ATCC13311Colorimetric Microbial Viability Assay1.16--4.00mg/ml/1.16--4.00mg/ml(Cilerdzic et al. [2016](#CIT0006))*G. lucidium*96%EtOHMycelia extract*B. cereus* (clinical isolate), *M. flavus*ATCC10240, *S. aureus*ATCC6538, *L. monocytogenes*NCTC7973, *E. coli* ATCC35218, *E. cloacae* (human isolate), *P. aeruginosa*ATCC27853 *and S. typhimurium*ATCC13311Colorimetric Microbial Viability Assay1.00--1.67mg/ml/1.16-400mg/ml(Cilerdzic et al. [2016](#CIT0006))*G. colossusm*CH~2~Cl~2~, MeOH, H~2~OFruiting bodies*S. aureus*(ATCC 29213), *B. subtilis*(ATCC 6059), *E. coli* (ATCC 25922),*P. aeruginosa*(ATCC 27853), *M. flavus*(SBUG 16)Agar DiffusionND(Al-Fatimi et al. [2005](#CIT0002))*G. resinaceum*CH~2~Cl~2~, MeOH, H~2~OFruiting bodies*S. aureus (ATCC 29213), B. subtilis*(ATCC 6059), *E. coli* (ATCC 25922),*P. aeruginosa*(ATCC 27853), *M. flavus*(SBUG 16)Agar DiffusionND(Al-Fatimi et al. [2005](#CIT0002))*G. applanatum*MeOHFruiting bodies*E.coli*(ATCC 25922)Micro dilutionND(Zengin et al. [2015](#CIT0045))*G.lucidum*EtOH and H~2~OFruiting bodies*S. aureus*(MTCC 96), *B. cereus* (MTCC 430), *P. aeruginosa*(MTCC 424)Micro dilution80-200mg/ml/ND(Karwa & Rai [2012](#CIT0018))*G. lucidum*Hexane and chloroformFruiting bodies*S. aureus*(ATCC 6538), *B. subtilis*(ATCC 6633)Agar Diffusion6.25mg/ml/ND(Vazirian et al. [2014](#CIT0041))*G. lucidum*Hexane and chloroformErgosta-5,7,22-trien-3β-yl acetate(**11**),ergosta-7,22-dien-3*β*-yl acetate(**70**),ergosta-7,22-dien-3-one(**15**),\
ergosta-7,22-dien-3β-ol(**13**), ergosta-5,7,22 trien,-3β-ol(**12**), ganodermadiol(**20**)*S. aureus*(ATCC 6538), *B. subtilis*(ATCC 6633) 2.5-5mg/ml/ND(Vazirian et al. [2014](#CIT0041))*G.lucidum*Hot H~2~OCarpophores*B. anthracis*ATCC 6603, *B. cereus* ATCC 27348, *B. subtilis*ATCC 6633, *M. luteus* ATCC 9341, *S. aureus* ATCC 25923,*E.coil*ATCC 259 22, *K. oxytoca*ATCC 8724, *K. pneumoniae*ATCC 10031, *P. vulgaris* ATCC 27853, *S. typhi*ATCC 6229Micro dilution1.25--5.0mg/ml/ND(Yoon et al. [1994](#CIT0044))*G. lucidium*96% EtOHBasidiocarps*B. cereus* (clinical isolate), *M. flavus*ATCC10240, *S. aureus*ATCC6538, *L. monocytogenes*NCTC7973, *E. coli* ATCC35218, *E. cloacae* (human isolate), *P. aeruginosa*ATCC27853 & *S. typhimurium*ATCC13311Disc-diffusion & Micro dilution1--3.4mg/ml/1.4--4.0mg/ml(Ćilerdžić et al. [2014](#CIT0005))*G.lucidium*95% EtOH12b-acetoxy-3*β*,7 *β* -dihydroxy-11,15,23-trioxolanost-8-en-26-oic acid butyl ester(**71**)*S. aureus*(ATCC 6538) & *B.subtilis*(ATCC6633)Micro dilution68.5 *µ*M&123.8 *µ*M(Liu et al. [2014](#CIT0023))*G. lucidum*MeOHNG*S. aureus*(ATCC 6538),*B.cereus*(clinical isolate), *L. monocytogenes*(NCTC 7973), *M. flavus*(ATCC 10240), *P. aeruginosa*(ATCC 27853), *E. coli* (ATCC 35210), *S. typhimurium*(ATCC 13311), *E. cloacae* (human isolate)Micro dilution0.0125--0.75mg/ml/0.035--1.5mg/ml(Heleno et al. [2013](#CIT0013))*G. lucidium*H~2~OMycelia(Protein extract)*S. epidermidis, B. subtilis, B .cereus E. coli, P. aeruginosa*Micro dilution20--81.5mg/ml/ND(Sa-Ard et al. [2015](#CIT0034))*G. lucidium*H~2~OFruiting bodies(Protein extract)*S. epidermidis, S. aureus, B. subtilis, B. cereus, E. coli, P. aeruginosa* 81.5-512mg/ml/ND(Sa-Ard et al. [2015](#CIT0034))*G. orbiforme*MeOH, EtOAc, AcetoneMycelia\#*M. tuberculosis*Green Fluorescent Protein Micro Plate Assay0.781-50*µ*g/mL/ND(Isaka et al. [2016](#CIT0016))[^1] Table 2.Illustration of antifungal activities of *Ganoderma* sp. parts, products and compounds.*Ganoderma*sp.Extraction SolventParts/products/compoundsTested Fungal strainsMethodAntifungal Concentration/ZOI/MIC/MFC/EC~50~ valueReferences*G. colossus*MeOHFruiting\
bodies*C. maltosa*Agar Diffusion Assay8mm/2mg/disc-ZOI(Al-Fatimi et al. [2005](#CIT0002))*G*. *applanatum*MeOH& H~2~ONG*C. albicans and C. parasilopsis*Broth Micro dilution1.25 & 2.5mg/ml-Antifungal activity(Zengin et al. [2015](#CIT0045))*G*. *resinaceum*MeOH& H~2~ONG*C. albicans and C. parasilopsis*Broth Micro dilution1.25 & 2.5mg/ml-Antifungal activity(Zengin et al. [2015](#CIT0045))*G*. *lucidium*96%EtOHFruiting bodies*Acremonium strictum*BEOFB10m, *A. glaucus*BEOFB21m, *A. flavus*BEOFB22m, *A.fumigatus*BEOFB23m, *A.nidulans*BEOFB24m, *A.niger*BEOFB25m, *A. terreus*BEOFB26m, *T. viride*BEOFB61mDisc-diffusion & Micro dilution0.5-308mg/ml-MIC; 1.0--4.0mg/ml-MFC(Ćilerdžić et al. [2014](#CIT0005))*G.lucidium*MeOHFruiting bodies*A. fumigatus*(human isolate), *A. versicolor*(ATCC 11730), *A. zochraceus*(ATCC 12066), *A. niger*(ATCC 6275), *T. viride*(IAMz5061), *P. funiculosum*(ATCC 36839), *P. ochrochloron*(ATCC 9112)*and P. verrucosum var*. cyclopium (food isolate)Micro dilution0.005--1.5mg/ml-MIC; 0.1--4.5mg/ml-MFC(Heleno et al. [2013](#CIT0013))*G.lucidium*EtOH& chemical synthesisRE--CGAP(RE: La, EuandYb)*V. mali, F. oxysporum, G. graminis, C. gloeosporioides, A. brassicae*Disc diffusion1.85--568.30mg/ml-EC~50~(Sun et al. [2014](#CIT0040))*G.lucidium*dH~2~OGanodermin*Botrytis cinerea, F. oxysporum and Physalo sporapiricola*Paper Disks8.1--12.4mM-Antifungal(Wang & Ng [2006](#CIT0042))*G.annulare*NGApplanoxidic acids A(**1**), C(**2**) & F(**3**)*M. cannis & T. mentagrophytes*Micro dilution500 to 1000mg/ml-Antifungal(Smania et al. [2003](#CIT0039))*G*. *applanatum*96%EtOHMycelia*Acremonium strictum, A. glaucus, A. flavus, A. fumigatus, A. nidulans, A. niger, A. terreus, T. viride*Colorimetric1.00--2.00mg/ml-MIC; 1.17--4.00mg/ml-MFC(Cilerdzic et al. [2016](#CIT0006))*G*. *carnosum*96%EtOHMycelia*Acremonium strictum, A. glaucus, A. flavus, A. fumigatus, A. nidulans, A. niger, A. terreus, T. viride*Colorimetric0.83--2.00mg/ml- MIC; 2.00--3.33mg/ml-MFC(Cilerdzic et al. [2016](#CIT0006))*G*. *lucidum*96%EtOHMycelia*Acremonium strictum, A. glaucus, A. flavus, A. fumigatus, A. nidulans, A. niger, A. terreus, T.viride*Colorimetric0.50--2.00mg/ml- MIC; 1.17--4.00mg/ml-MFC(Cilerdzic et al. [2016](#CIT0006))[^2] Table 3.Illustration of antiviral activities of *Ganoderma* sp. parts, products and compounds.*Ganoderma*sp.Tested Viral strainsExtraction SolventParts/products/compoundsMethodIC~50~ (≤50*µ*M)/EC~50~/ED~50~ valueReferences*G. sinense*HIV 1(HIV-1 protease)CHCl~3~Ganoderic acid GS-2(**48**), 20-hydroxylucidenic acid N(**74**), 20(21)-dehydrolucidenic acid N(**39**) & ganoderiol F(**22**)*In vitro* (Enzymatic)20 -- 40*µ*M(Sato et al. [2009](#CIT0036))*G. colossum*HIV 1(HIV-1 protease)CHCl~3~Colossolactone V(**10**), Colossolactone VII(**8**), Colossolactone VIII(**7**), Schisanlactone A(**33**), Colossolactone G(**5**), Colossolactone A(**9**)*In vitro* (Enzymatic)5-39*μ*g/mL(El Dine et al. [2008](#CIT0008))*G. colossum*HIV 1(HIV-1 protease)CHCl~3~Ganomycin I(**29**) &Ganomycin B(**28**)*In vitro* (Enzymatic)7.5 and 1.0 *μ*g/mL(El Dine et al. [2009](#CIT0009))*G.lucidium*HIV 1(HIV-1 protease)MeOHGanoderiol F(**21**) &Ganodermanontriol(**23**)*In vitro* (Enzymatic)7.8*μ*g/mL(El-Mekkawy et al. [1998](#CIT0010))*G. lucidum*Herpes Simplex Virus types 1 (HSV-1) and 2 (HSV-2), Influenza A virus (Flu A) and Vesicular Stomatitis Virus (VSV) Indiana and New Jersey strainsH~2~O &MeOHCarpophoresCytopathic Effect (CPE) Inhibition Assay & Plaque Reduction Assay68-1790*μ*g/mL-EC50(Eo et al. [2000](#CIT0011))*G. lucidum*HSV-1 and HSV-2H~2~O/EtOHAcidic protein bound\
polysaccharidePlaque Reduction Assay (Eo et al. [2000](#CIT0011))*G. lucidum*Oral Human Papillomavirus (HPV)NGFruiting bodies*In vivo* (Human)87% clearance of virus(Donatini [2014](#CIT0007))*G. lucidum*Newcastle Disease Virus(anti-neuraminidase)MeOH, EtOAc & Butanol *In vitro*Virus dilution ratio(1:16, 1:16, 1:32)(Shamaki et al. [2014](#CIT0037))*G. lucidum*Epstein-Barr\
VirusMeOHFruiting bodies\**In vitro*96--100% at 1 103 mol ratio/TPA(Iwatsuki et al. [2003](#CIT0017))*G. lucidum*Hepatitis B virusNGmycelia*In vitro* (HepG2 cells)IRA(HBsAg, HBeAg) up to 100%(Y. Li et al. [2006](#CIT0021))*G. lucidum*Hepatitis BH~2~Oand CHCl~3~mycelia(Ganoderic acid)*In vitro* (HepG2215)Inhibition of production of HBV surface antigen and HBVe at 8*μ*g/mL(Y.-Q. Li & Wang [2006](#CIT0022))*G. pfeifferi*Influenza virus type A and HSV type 1NGGanodermadiol(**20**), lucidadiol (**30**) & applanoxidic acid G(**4**)Dye Uptake AssayInfluenza ED50(0.19--0.22mmol/l); HSV 1(0.068 mmol/l for ganodermadiol)(MothanaRa et al. [2003](#CIT0027))*G. pfeifferi*HSV type 1CH~2~Cl~2~Ganoderone A(**25**), Lucialdehyde B(**31**), Ergosta-7,22-dien-3α-ol(**14**), Ganoderol A(**21**) & Ganoderol B(**51**)*In vitro* (Vero cells)0.03--0.75*μ*g/mL(IC50)(Niedermeyer et al. [2005](#CIT0028))*G. pfeifferi*Influenza virus type ACH~2~Cl~2~Ganoderone C(**26**), Lucialdehyde B(**31**) & Ergosta-7,22-dien-3α-ol(**14**)*In vitro* (MDCK cells))0.78--2.6*μ*g/mL(IC50)(Niedermeyer et al. [2005](#CIT0028))*G. lucidum*Enterovirus 71NGLanosta-7,9(11),24-trien-3-\
one,15;26-dihydroxy (GLTA)(**40**), Ganoderic acid Y(**19**)*In vitro* (Human Rhabdomyosarcoma)0.16 to 4 *μ*g/ml(IC50)(W. Zhang et al. [2014](#CIT0047))[^3] Table 4.Details of anti-parasitic activities of *Ganoderma* sp. parts and compounds.*Ganoderma*sp.Extraction SolventParts/compoundsTest ParasiteMethodLD~50~/IC~50~ valueReferences***Ganoderma*sp.**EtOAc&MeOHFruiting bodies(schisanlactone B(**32**), Ganodermalactone F(**24**), colossolactone E(**6**))*P. falciparum*Micro culture Radioisotope Technique6.0--10.0 *μ*M(Lakornwong et al. [2014](#CIT0019))***G. lucidum***EtOAc&MeOHFruiting bodies\**P. falciparum*Micro culture Radioisotope Technique6.0-20*μ*M(Adams et al. [2010](#CIT0001))***G. boninense***EtOHGanoboninketals A(**75)** Ganoboninketals B-C(**16--17**)*P. falciparum*DNA Fluorescence\
Signal Test4.0, 7.9, and 1.7 *μ*M(Ma et al. [2014](#CIT0024))***G. lucidum***EtOHCrude extract*P. bergheiIn Vivo* Malarial activity (Oluba et al. [2012](#CIT0031))***G.lucidum***NGLectin*H. glycines*Parasite Mortality Test(\>10 mg/ml/2hrs,4.5 mg/ml/24hrs, 1.7 mg/ml/48hrs(Zhao et al. [2009](#CIT0048))***G. lucidum***NGLectin*D. dipsaci*Parasite Mortality Test\>10 mg/ml(Zhao et al. [2009](#CIT0048))[^4] Figure 3.Flowchart of isolation of antimicrobial and anti-parasitic compounds from *Ganoderma* sp.

4.. Antibacterial activities of compounds and extracts of *Ganoderma* sp {#S0004}
========================================================================

Currently bioassay-guided antibiotics identification, TLC and chromatography bio-autography are used to track antibacterial ingredients from the extract (Huie & Di [2004](#CIT0015)). Minimum inhibitory concentration (MIC) and 50% inhibitory concentration (IC~50~) values are used to determine the potency of antibacterial agents. Our literatures review showed that MeOH and EtOH are good solvents for the extraction of antibacterial compounds of interest rather than other organic solvents; however, the parts of *Ganoderma* sp. used and the tested bacterial strains may be the limiting factors in choosing the solvent. Most studies that use alcoholic solvents for extraction showed very low MIC (Li et al. [2012](#CIT0020); Shang et al. [2013](#CIT0038); Cilerdzic et al. [2016](#CIT0006)). Several studies on the fruiting bodies of *Ganoderma* sp. reveal that the compounds have the inhibitory ability to the different types of Gram positive bacteria (GPB), Gram negative bacteria (GNB) including the mycobacteria (Al-Fatimi et al. [2005](#CIT0002); Isaka et al. [2016](#CIT0016)).

Colossolactone E (**6**) and 23-hydroxycolossolactone E (**53**), two colossolactones-triterpenes, were active against *Bacillus subtilis* and *Pseudomonas syringae*. However, the researcher did not determine the MIC and MBC of compounds against this bacterium (Ofodile et al. [2011](#CIT0029)). Moreover, two hydroquinones, ganomycins A (**27**) and B (**28**), were found to be the most effective to inhibit the bacterium. The MIC values of compounds **27** and **28** were 25 *µ*g/ml against *Staphylococcus aureus* and 2.5 *µ*g/ml against *Micrococcus flavus,* respectively, taking positive control ampicillin (MIC = 0.05 *µ*g/ml and 0.25 *µ*g/ml for *S. aureus* and *M. flavus,* respectively). In addition, in agar diffusion assay Zone of Inhibition (ZOI) 15--25 mm/100 *µ*g/paper disk was found for GPB such as *B. subtilis, S. aureus* and *M. flavus*. However, *P. aeruginosa, Candida albicans* and *C. maltose* at 100 *µ*g/paper disk did not respond to these compounds (Mothana et al. [2000](#CIT0026)). In a work performed by Isaka et al. ([2016](#CIT0016)), EtOAc and MeOH extract of *Ganoderma* sp. BCC 16,642 isolated different compounds astraodoric acid C (**50**), ganorbiformin F (**72**), ganoderic acid TR (**34**), ganoderic acid T (**73**), ganoderic acid S (**18**), lanostanoid, ((22*S*,24*E*)-3*β*,15*α*,22-triacetoxylanosta-8,24-dien-26-oic acid (**45**), (24*E*)-3*β*-acetoxy-7*α*-hydroxylanosta-8,24-dien-26-oic acid (**44**), (24*E*)-3*β*,15*α*-diacetoxy-7*α*-hydroxylanosta-8,24-dien-26-oic acid (**43**), (22*S*,24*E*)-7*α*-hydroxy-3*β*,15*α*,22-triacetoxylanosta-8,24-dien-26-oic acid (**42**), (22*S*,24*E*)-3*β*,22-diacetoxy-7*α*-methoxylanosta-8,24-dien-26-oic acid (**46**), (22*S*,24*E*)-7*α*-methoxy-3*β*,15*α*,22-triacetoxylanosta-8,24-dien-26-oic acid (**47**), (22*S*,24*E*)-3*β*,22-diacetoxylanosta-7,9(11),24-trien-26-oic acid (**41**), which were observed to be active against the *Tubercular bacilli* with the MIC value in the range of 0.781--50 *µ*g/ml. In another study, steroidal compounds like ergosta-5,7,22-trien-3*β*-yl acetate (**11**), ergosta-5,7,22-dien-3*β*-yl acetate (**70**), ergosta-7,22-dien-3-one (**15**), ergosta-7,22-dien-3*β*-ol (**13**), ergosta-5,7,22-trien-3*β*-ol (**12**) and ganodermadiol (**20**) were found to be effective against *S. aureus* and *B. subtilis* with MIC value of 2.5--5 mg/ml (Vazirian et al. [2014](#CIT0041)). Ethanolic and EtOAc extract compounds 12*β*-acetoxy-3*β*, 7*β*-dihydroxy-11, 15, 23-trioxolanost-8-en-26-oic acid butyl ester (**71**) from fruiting bodies of *G. lucidium* showed significant inhibition against *S. aureus* and *B. subtilis* with MIC values of 68.5 *µ*M and 123.8 *µ*M, respectively (positive control ampicillin = 4.1 *µ*M and 19.3 *µ*M, resp.) (Liu et al. [2014](#CIT0023)).

Literatures reveal most of the antibacterial tests are performed on crude extract with significant effective results rather than pure compounds (Sa-Ard et al. [2015](#CIT0034); Zengin et al. [2015](#CIT0045); Cilerdzic et al. [2016](#CIT0006)). In addition, scanty information is available on the in vivo model test of effective compounds; we noticed only compounds (**27**) and **28** have been tested the in vivo model of the Methicillin-resistant Staphylococcus aureus (MRSA)-infected mouse (Mikolasch et al. [2016](#CIT0025)).

5.. Antifungal activities of compounds and extracts of *Ganoderma* sp {#S0005}
=====================================================================

An antifungal protein -- ganodermin -- isolated from the fruiting bodies of *G. lucidium* inhibits the growth of *Botrytis cinerea, Fusarium oxysporum* and *Physalo sporapiricola* with an IC~50~ value of 15.2 mM, 12.4 mM and 18.1 mM, respectively (Wang & Ng [2006](#CIT0042)). Terpeneoids like applanoxidic acids A (**1**), C (**2**) and F (**3**) isolated from *G. annulare* inhibit the growth of the fungi *Microsporum cannis* and *Trichophyton mentagrophytes* at concentrations of 500--1000 *µ*g/ml (Smania et al. [2003](#CIT0039)).

In another study, researchers synthesised the complexes of polysaccharide with different rare earth metal (RE--CGAP (RE: La, Eu and Yb)) and evaluated their efficacy against fungi and reported that rare earth carboxymethylated *G. Applanatum* polysaccharide (RE-CGAP) complexes with antifungal activities with EC~50~ value of 1.01--28.48 mg/ml (\>100 mg/ml not included) (Sun et al. [2014](#CIT0040)). The details of the antifungal action of *Ganoderma* sp. are demonstrated in [Table 2](#T0002).

6.. Antiviral activities of compounds and extracts from *Ganoderma* sp {#S0006}
======================================================================

It is interesting to note that the majority of antiviral investigations on *Ganoderma* sp. have been performed from fruiting body against the protease enzyme of HIV virus. The compounds ganoderiol F (**22**) and ganodermanontriol (**23**) were found to be active as anti-HIV-1 agents with an inhibitory concentration of 7.8 *µ*g/ml. In addition, in the same experiment ganoderiol B (**51**), ganoderiol A (**21**), ganoderic acid A (**76**), ganoderic acid B (**77**), ganoderic acid C1 (**78**) and ganoderic acid H (**79**) were found to be moderate in their efficacy (El-Mekkawy et al. [1998](#CIT0010); El Dine et al. [2008](#CIT0008)). Colossolactone types of triterpenoids such as colossolactone V (**10**), colossolactone VII (**8**), colossolactone VIII (**7**), schisanlactone A (**33**), colossolactone G (**5**) and colossolactone A (**9**) were isolated from the chloroform extract from *G. lucidium* with and IC~50~ value of 5--39 *μ*g/ml (El Dine et al. [2008](#CIT0008)). Similarly in Sato et al. ([2009](#CIT0036)), isolated lanostane-type triterpenoids-ganoderiol F (**22**), ganoderic acid GS-2 (**48**) and 20-hydroxylucidenic acid N (**74**), 20(21)-dehydrolucidenic acid N (**39**) from CHCl~3~ extract of the fruiting body of *G. sinense* and demonstrated the anti-HIV-1 protease activity with IC~50~ values of 20--40 *μ*M (El Dine et al. [2008](#CIT0008); Sato et al. [2009](#CIT0036)). Compounds from the CHCl~3~ extract of the fruiting bodies of *G. colossum*, farnesyl hydroquinone, ganomycin I (**29**) and ganomycin B (**28**), competitively inhibit the active site of HIV-1 protease enzyme with IC~50~ values of 7.5 and 1.0 *μ*g/ml, respectively (El Dine et al. [2008](#CIT0008)).

*Ganoderma pfeifferi* triterpenes, ganodermadiol (**20**), lucidadiol (**30**) and applanoxidic acid G (**4**), were active against influenza virus type A with ED~50~ of greater than 0.22 mM, 0.22 mM and 0.19 mM, respectively (MothanaRa et al. [2003](#CIT0027)). Similarly others triterpenes such as ganoderone C (**26**) (IC~50~: 2.6 *µ*g/ml), lucialdehyde B (**31**) (IC~50~:3.0 *µ*g/ml) and ergosta-7, 22-dien-3*α*-ol (**14**) (IC~50~: 0.78 *µ*g/ml) inhibited the growth of Madin-Darby canine kidney (MDCK) cells infected with influenza virus (Niedermeyer et al. [2005](#CIT0028)). Herpes simplex virus were inhibited by triterpenes such as compound (**20**) (ED~50~: 0.068 mM), ganoderone A (**25**) (IC~50~:0.075 *µ*g/ml), (**31**) (IC~50~:0.03 *µ*g/ml) and compound **14** (IC~50~: 0.03 *µ*g/ml), whereas compounds **21** and **51** were less effective in comparison (MothanaRa et al. [2003](#CIT0027); Niedermeyer et al. [2005](#CIT0028)). *G. lucidium* triterpenes lanosta-7, 9 (11), 24-trien-3-one, 15; 26-dihydroxy (GLTA) (**40**) and ganoderic acid Y (**19**) possess inhibitory action towards enterovirus 71 with IC~50~ value of 0.16--4 *μ*g/ml (Zhang et al. [2015](#CIT0046)). The details of the antiviral activities of *Ganoderma* sp. have been illustrated in [Table 3](#T0003).

7.. Anti-parasitic activities of compounds and extracts from *Ganoderma* sp {#S0007}
===========================================================================

Nortriterpenes-ganoboninketals A-C (**15--17**) obtained from the biochemical analysis of the fruiting bodies of *G. boninense* were found to possess anti-parasitic activity against *P. falciparum* with IC~50~ values of 4.0, 7.9 and 1.7 *μ*M, respectively (Adams et al. [2010](#CIT0001); Ma et al. 2014). Similarly three triterpenes -- schisanlactone B (**32**), ganodermalactone F (**24**) and colossolactone E (**6**) -- isolated with EtOAc and MeOH from *Ganoderma* sp. KM01 are active against *P. falciparum* in the range 6.0−10.0 *μ*M (Lakornwong et al. [2014](#CIT0019)a). In addition, *G. lucidium* terepenes -- ganoderic acid DM (**35**), ganoderic acid TR1 (**52**), ganoderic aldehyde TR (**37**), ganoderic acid S (**18**), ganodermanondiol (**38**) and ganofuran B (**49**) -- isolated from EtOAc inhibit *P. falciparum* with IC~50~ value of range 6.0--20 *μ*M (Adams et al. [2010](#CIT0001)). In a recent study, Zhao et al. found lectin to be active against the plant nematodes *Heterodera glycines* and *Ditylenchus dipsaci*, though their potency was not significant to be used practically (Zhao et al. [2009](#CIT0048)) .

8.. Conclusion and future perspective {#S0008}
=====================================

*Ganoderma* sp. has been used for treatment in various diseases over a long period (Paterson [2006](#CIT0032)). Our review clearly showed that compounds from *Ganoderma* sp., under the extensive in vivo and pharmacological research, can be used in various microorganisms and parasitic diseases. However, the in vivo experiment and pharmacological research of the identified compounds are very limited. Therefore, future work should be focused on in vivo and pharmacological assays of known compounds, especially Ganoderma terpenes that have antimicrobial and anti-parasitic properties. A better understanding of the antimicrobial and anti-parasitic compounds from *Ganoderma* sp. is crucial for identifying the potential side effects and trace out the new host target and molecular mechanisms, which will provide evidence to further clinical applications of these compounds.

Although extensive researches have been carried out on *Ganoderma* sp., most of the studies were concentrated on few species, *G. lucidum* for instance. Researchers must need to pay more attention to closely related species based on the phylogenic analysis though numerous challenges including genetic analysis, biosynthetic metabolism, separation, isolation and identification may be encountered. In addition, due to the rapid emergence of drug resistance in microorganisms and parasites, fewer options have been left for the treatment of diseases caused by microorganism and parasites. To fight back this problem, further research should be focused on this field for all the identified compounds and the unidentified compounds, which are on the way to be identified. Our review revealed numerous extracts of *Ganoderma* sp. exhibit the inhibition to microorganisms including parasites, indicating that *Ganoderma* sp. in particular still seem to possess opportunities for new drug lead compounds.

Scanty literatures are found on the assay of identified compounds for animal and plants pathogens including parasites, indicating that this area of research for the *Ganoderma* sp. compounds is overlooked. Also, our current experience on a literatures review of *Ganoderma* sp. compounds, more than 430 compounds identified (Baby et al. [2015](#CIT0003); Rai et al. [2015](#CIT0033)), most of the compounds have not been performed on the antimicrobial and anti-parasite assay. Therefore, further studies need to be carried out in order to explore this concealed area.

No doubt, it is evident that *Ganoderma* sp. is going to serve as one of the potential sources of novel antibiotics and anti-parasitic drugs in the near future. To reach the apex and specificity of effective antimicrobial and anti-parasite activity, cooperative investigations need to be carried out in the areas of genomic, bioinformatics, chemistry and pharmacology. Moreover, strategies to evoke the sleeping gene clusters linked for the production of bioactive compounds and its regulation need to be adopted.
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[^1]: MeOH-Methanol; EtOH-Ethanol; dH~2~O- Distilled water; NG- Data Not Given; ZOI-Zone Of Inhibition; MIC- Minimum Inhibitory Concentration; MBC- Minimum Bactericidal Concentration; *S. aureus- Staphylococcus aureus; B. subtilis- Bacillus subtilis*;, \#(astraodoric acid B(**50**), ganorbiformin F(**72**), ganoderic acid TR(**34**), ganoderic acid T(**73**), ganoderic acid S(**18**), (22*S*,24*E*)-3*β*,15*α*,22-triacetoxylanosta-8,24-dien-26-oic acid(**41**), (24*E*)-3*β*-acetoxy-7*α*-hydroxylanosta-8,24-dien-26-oic acid(**44**), (24*E*)-3*β*,15*α*-diacetoxy-7*α*-hydroxylanosta-8,24-dien-26-oic acid(**43**), (22*S*,24*E*)-7*α*-hydroxy-3*β*,15*α*,22-triacetoxylanosta-8,24-dien-26-oic acid(**42**), (22*S*,24*E*)-3*β*,22-diacetoxy-7*α*-methoxylanosta-8,24-dien-26-oic acid(**46**), (22*S*,24*E*)-7*α*-Methoxy-3*β*,15*α*,22-triacetoxylanosta-8,24-dien-26-oic acid(**47**), (22*S*,24*E*)-3β,22-diacetoxylanosta-7,9(11),24-trien-26-oic acid(**45**).

[^2]: MeOH: Methanol; EtOH: Ethanol; dH~2~O: Distilled water; NG: Data Not Given; ZOI: Zone Of Inhibition; MIC: Minimum Inhibitory Concentration; MFC: Minimum Fungicidal Concentration; EC~50~: Concentration; RE--CGAP: Rare Earth-CarboxymethylatedGanodermaapplanatum Polysaccharide; *μ*M: Micro Mole; mg/ml: milligram/millilitre.

[^3]: MeOH: Methanol; EtOH Ethanol; H~2~O: water; NG: Data Not Given; IC~50~: half-maximal Inhibitory Concentration; EC~50~: half-maximal Effective Concentration; ED~50~: median effective dose; *μ*M: Micro Mole; mg/m: -Milligram/Millilitre; *μ*g/ml: Microgram/millilitre; \*(Lucidenic acid P(**58**), Methyl lucidenate P(**59**), Methyl lucidenate Q(**60**), Lucidenic acid A(**61**), Methyl lucidenate A(**62**), Lucidenic acid C(**63**), Lucidenic acid D2(**64**), Methyl lucidenate D2(**65**), Lucidenic acid E2(**66**), Methyl lucidenate E2(**67**), Methyl lucidenate F(**68**), Methyl lucidenate L(**69**), Ganoderic acid E(**54**), Ganoderic acid F(**57**), Methyl ganoderate F(**56**), Ganoderic acid T-Q(**54**)).

[^4]: EtoAc: Ethyl Acetate; EtOH: ethanol; MeOH: Methanol; *P. falciparum*: *Plasmodium falciparum; H. glycines*: *Heteroderaglycines; D. dipsaci*: *Ditylenchusdipsaci*; NG: Data Not Given; *μ*M: Micro Mole; mg/ml: milligram/millilitre; \*(Ganodericacid DM(**35**), Ganoderic Acid TR 1(**52**),Ganoderic Aldehyde TR(**37**),23-Hydroxyganoderic Acid S(**36**), Ganoderic acid S(**18**), Ganodermanondiol(**37**), Ganofuran B(**49**)).
